Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy.

Daniel Tobias Michaeli Julia Caroline Michaeli Tobias Boch Thomas Michaeli

Published in: Clinical drug investigation (2022)

Icosapent ethyl is cost effective for primary and secondary cardiovascular prevention at an annual price of £2064 in the UK. For PCSK9 inhibitors, price discounts or prescription restrictions are necessary to achieve cost effectiveness.

Keyphrases

low density lipoprotein
cardiovascular disease
ionic liquid
coronary artery disease
combination therapy
cross sectional
clinical trial
double blind